Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 Feb 2022
Historique:
entrez: 28 2 2022
pubmed: 1 3 2022
medline: 21 4 2022
Statut: epublish

Résumé

Intrauterine device (IUD) expulsion increases the risk of unintended pregnancy; how timing of postpartum IUD insertion and breastfeeding are associated with risk of expulsion is relevant to the benefit-risk profile. To evaluate the association of postpartum timing of IUD insertion and breastfeeding status with incidence and risk of IUD expulsion. The Association of Perforation and Expulsion of Intrauterine Devices (APEX-IUD) cohort study included women aged 50 years or younger with an IUD insertion between 2001 and 2018. The breastfeeding analysis focused on a subcohort of women at 52 or fewer weeks post partum with known breastfeeding status. The study was conducted using data from electronic health records (EHRs) at 4 research sites with access to EHR: 3 Kaiser Permanente sites (Northern California, Southern California, Washington) and the Regenstrief Institute (Indiana). Data analysis was conducted from June to November 2019. Timing of IUD insertion post partum was categorized into discrete time periods: 0 to 3 days, 4 days to 6 or fewer weeks, more than 6 weeks to 14 or fewer weeks, more than 14 weeks to 52 or fewer weeks, and non-post partum (>52 weeks or no evidence of delivery). Breastfeeding status at the time of insertion was determined from clinical records, diagnostic codes, or questionnaires from well-baby visits. Incidence rates and adjusted hazard ratios (aHRs) were estimated using propensity scores to adjust for confounding. The full cohort included 326 658 women (mean [SD] age, 32.0 [8.3] years; 38 911 [11.9%] Asian or Pacific Islander; 696 [0.2%] Hispanic Black; 56 180 [17.2%] Hispanic other; 42 501 [13.0%] Hispanic White; 28 323 [8.7%] non-Hispanic Black; 137 102 [42.0%] non-Hispanic White), and the subcohort included 94 817 women. Most IUDs were levonorgestrel-releasing (259 234 [79.4%]). There were 8943 expulsions. The 5-year cumulative incidence of IUD expulsion was highest for insertions 0 to 3 days post partum (10.73%; 95% CI, 9.12%-12.61%) and lowest for insertions more than 6 weeks to 14 or fewer weeks post partum (3.18%; 95% CI, 2.95%-3.42%). Adjusted HRs using women with non-post partum IUD insertion as the referent were 5.34 (95% CI, 4.47-6.39) for those with postpartum insertion at 0 to 3 days; 1.22 (95% CI, 1.05-1.41) for those with postpartum insertion at 4 days to 6 or fewer weeks; 1.06 (95% CI, 0.95-1.18) for those with postpartum insertion at more than 6 to 14 or fewer weeks; and 1.43 (95% CI, 1.29-1.60) for those with postpartum insertion at more than 14 to 52 or fewer weeks. In the subcohort, 5-year cumulative incidence was 3.49% (95% CI, 3.25%-3.73%) for breastfeeding women and 4.57% (95% CI, 4.22%-4.95%) for nonbreastfeeding women; the adjusted HR for breastfeeding vs not breastfeeding was 0.71 (95% CI, 0.64-0.78). In this study of real-world data, IUD expulsion was rare but more common with immediate postpartum insertion. Breastfeeding was associated with lower expulsion risk.

Identifiants

pubmed: 35226086
pii: 2789453
doi: 10.1001/jamanetworkopen.2021.48474
pmc: PMC8886522
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2148474

Références

Cochrane Database Syst Rev. 2015 Jun 26;(6):CD003036
pubmed: 26115018
Eur J Contracept Reprod Health Care. 2020 Dec;25(6):439-444
pubmed: 33006501
Contraception. 2011 May;83(5):397-404
pubmed: 21477680
N Engl J Med. 2012 May 24;366(21):1998-2007
pubmed: 22621627
Am J Obstet Gynecol. 2020 Aug;223(2):177-188
pubmed: 32142826
Am J Obstet Gynecol. 2021 Jun;224(6):599.e1-599.e18
pubmed: 33460585
Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):771-780
pubmed: 29655187
Best Pract Res Clin Endocrinol Metab. 2017 Aug;31(4):367-384
pubmed: 29221566
Obstet Gynecol. 2011 Nov;118(5):1014-1020
pubmed: 22015868
Acta Obstet Gynecol Scand. 2021 Apr;100(4):596-603
pubmed: 33421091
Int J Gynaecol Obstet. 2014 Aug;126(2):165-9
pubmed: 24825498
Contraception. 2015 Dec;92(6):532-5
pubmed: 26408376
Int J Gynaecol Obstet. 2020 May;149(2):154-159
pubmed: 32037531
Obstet Gynecol. 2016 Aug;128(2):e32-7
pubmed: 27454734
J Magn Reson Imaging. 2017 Feb;45(2):617-623
pubmed: 27417879
Pharmacoepidemiol Drug Saf. 2013 May;22(5):542-50
pubmed: 23526818
Contraception. 2016 Dec;94(6):725-738
pubmed: 27421765
Eur J Contracept Reprod Health Care. 2016 Oct;21(5):356-60
pubmed: 27367825
Clin Epidemiol. 2019 Jul 23;11:635-643
pubmed: 31413641
Obstet Gynecol Clin North Am. 2015 Dec;42(4):569-82
pubmed: 26598300
Stat Med. 1991 Mar;10(3):457-62
pubmed: 2028128

Auteurs

Mary Anne Armstrong (MA)

Division of Research, Kaiser Permanente Northern California, Oakland.

Tina Raine-Bennett (T)

Division of Research, Kaiser Permanente Northern California, Oakland.
Department of Health Systems Science, the Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.

Susan D Reed (SD)

University of Washington, Seattle.

Jennifer Gatz (J)

Regenstrief Institute, Indianapolis, Indiana.

Darios Getahun (D)

Department of Health Systems Science, the Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena.

Juliane Schoendorf (J)

Bayer OY, Espoo, Finland.

Debbie Postlethwaite (D)

Division of Research, Kaiser Permanente Northern California, Oakland.

Michael J Fassett (MJ)

Department of Obstetrics & Gynecology, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, California.
Department of Clinical Science, the Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.

Jeffrey F Peipert (JF)

Indiana University, Indianapolis.

Catherine W Saltus (CW)

RTI Health Solutions, Waltham, Massachusetts.

Maqdooda Merchant (M)

Division of Research, Kaiser Permanente Northern California, Oakland.

Amy Alabaster (A)

Division of Research, Kaiser Permanente Northern California, Oakland.

Xiaolei Zhou (X)

RTI Health Solutions, Research Triangle Park, North Carolina.

Laura Ichikawa (L)

Kaiser Permanente Washington Health Research Institute, Seattle.

Jiaxiao M Shi (JM)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena.

Vicki Y Chiu (VY)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena.

Fagen Xie (F)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena.

Shannon Hunter (S)

RTI Health Solutions, Research Triangle Park, North Carolina.

Jinyi Wang (J)

RTI Health Solutions, Research Triangle Park, North Carolina.

Mary E Ritchey (ME)

RTI Health Solutions, Research Triangle Park, North Carolina.

Giulia Chillemi (G)

Division of Research, Kaiser Permanente Northern California, Oakland.

Theresa M Im (TM)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena.

Harpreet S Takhar (HS)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena.

Federica Pisa (F)

Bayer AG, Berlin, Germany.

Alex Asiimwe (A)

Bayer AG, Berlin, Germany.

Mary S Anthony (MS)

RTI Health Solutions, Research Triangle Park, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH